Stoke Therapeutics
STOK
96 hedge funds and large institutions have $173M invested in Stoke Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 36 reducing their positions, and 20 closing their positions.
1,472% more call options, than puts
Call options by funds: $283K | Put options by funds: $18K
4% less funds holding
Funds holding: 100 → 96 (-4)
6.37% less ownership
Funds ownership: 105.33% → 98.96% (-6.4%)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
31% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 36
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less capital invested
Capital invested by funds: $495M → $173M (-$322M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$11.2M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.09M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.92M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.43M |
| 5 |
D.E. Shaw & Co
New York
|
+$583K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.24M |
| 3 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
-$3.68M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.66M |
| 5 |
AG
Artal Group
Luxembourg
|
-$2.66M |
STOK Hedge Fund Activity: Q3 2023 in Review
96 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2023, worth a combined $173M — down 65% from $495M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of STOK and 17 opened new positions — a net loss of 3 holders — while 36 trimmed existing stakes and 25 added.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $11.2M. The largest seller was Fidelity Investments, cutting an estimated $15.3M.
- 96 institutional investors held Stoke Therapeutics (STOK) as of Q3 2023, down from 100 in Q2 2023.
- Funds reported $173M of Stoke Therapeutics stock for Q3 2023, down 65% quarter-over-quarter.
- 17 funds opened new Stoke Therapeutics positions in Q3 2023 and 20 closed out, a net change of -3 holders.
- The largest Stoke Therapeutics buyer in Q3 2023 was Lynx1 Capital Management, an estimated $11.2M added.
- The largest Stoke Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2023.